



Department of Haematology  
University General Hospital of Ioannina  
St. Niarchou Av, 45500, Ioannina Greece  
+302651099656  
[Personal website](#)  
[ehatzim@uoi.gr](mailto:ehatzim@uoi.gr)

## Eleftheria Hatzimichael, MD, PhD

Eleftheria Hatzimichael, MD, PhD (born 1975) is a Haematologist, with a strong background and research activities in epigenetics and translational research and currently an **Associate Professor of Haematology**, in the Faculty of Medicine, School of Health Sciences, University of Ioannina Greece. She graduated from the School of Medicine, University of Ioannina in 1998 and was trained in Haematology at St. Bartholomew's Hospital, Barts and the London Trust, London, UK and the University Hospital of Ioannina, Ioannina, Greece. For her achievements on 2011, she was awarded a prestigious early-career one-year fellowship from the Hellenic Society of Haematology Foundation to work with Dr Isidore Rigoutsos as Visiting Scientist at the Computational Medicine Centre, Jefferson Medical College, Thomas Jefferson University, US, in the field of the non-coding human genome by computational and experimental approaches. She has also received the prestigious Clinical Research Training in Haematology award 2016-2017 by the European Haematology Association, 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope. She is the PI more than 30 Phase III and IV clinical trials and has served as a subinvestigator in more than 25 phase I-III clinical trials and as a reviewer for more than 27 journals. She is a member of the Associate Editorial Board of the *American Journal of Blood Research* and member of the Editorial Board of *Diseases* (section Oncology) and a member of the Hellenic Society of Haematology, the Greek Myeloma Study Group (GMSG), The Greek (Hellenic) MDS Group, the American Society of Hematology, the European Cancer Research Association, and the European Haematology Association. She is also the Secretary of the Steering Committee of the Scientific Department of Myelodysplastic Syndromes and Marrow Failure of the Hellenic Society of Hematology, 2022-2023, 2024-2025, and a Member of the Board of Directors of the Hellenic Society of Hematology, 2022-2024. She has more than 130 papers in peer-reviewed journals with an h-index (source Scopus) 33.

---

### Medical education

1992-1998	Medical School of Ioannina, University of Ioannina, Ioannina, Greece
Jul 1998	Medical License 9894/ 27-7-1998
Dec 2008	<b>PhD</b> , Medical School of Ioannina, University of Ioannina, Greece Title of thesis: " <i>Study of the expression and clinical significance of cyclins and the methylation status of cyclin inhibitors in haematological malignancies</i> "

---

### Education relevant to clinical research

### Appointments and Training

June 2023- up to now	Associate Professor of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece
Aug 2018 -June 2023	Assistant Professor of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece
Dec 2016- Aug 2018	Consultant Hematologist, Hematology Unit, General Hospital "G. Hatzikosta"
Oct 2014-Nov 2016	Academic Fellow, and Honorary Consultant, University of Ioannina, Ioannina Medical School, Ioannina Greece, Head: Prof E. Briasoulis
Mar 2013 - Mar 2014	Consultant Haematologist Department of Hematology, University Hospital of Ioannina, Greece, Head: Prof E. Briasoulis
Jan 2012 - Feb 2013	Scholar of the Hellenic Society of Haematology, Foundation – Visiting Scientist Computational Medicine Center, Jefferson Medical College, Philadelphia, PA, USA, PI: Prof. Isidore Rigoutsos
Feb 2011 - ongoing	Clinical and Translational Research leader, Department of Haematology, University Hospital of Ioannina, Head: Prof. E. Briasoulis
Feb 2010- Feb 2011	Consultant Haematologist Department of Hematology, University Hospital of Ioannina, Greece, Directors: Prof. K.L. Bourantas, Prof E. Briasoulis
March 2009	CCST- Board Certified in Haematology
Sep 2005 - Feb 2009	Trainee in Haematology, Department of Hematology, University Hospital of Ioannina, Greece, Director, Prof. K.L. Bourantas
Aug 2004 - Aug 2005	Clinical Research Fellow in Haematology Oncology, St. Bartholomew's Hospital, London, UK, Clinical Director: Prof T.A. Lister
July 2001 - Feb 2004	Senior House Officer in Internal Medicine, General Hospital "G. Hatzikosta", Ioannina, Greece, Head of the Department: Nikolaos K. Akritidis
Dec 1998 - Dec1999	House Officer in the Health Center of Konitsa, Ioannina, Greece
Sep 1998-Sep 1998	House Officer in "G. Hatzikosta" General Hospital, Ioannina, Greece rotating: Internal Medicine, Cardiology, Surgery

---

### Grants

1. Strategic expansion of the Greek Biobanking Infrastructure (BBMRI-GR). Funding G.G. of Research and Technology - "Strengthening of Research Infrastructures of National Scope" of the Operational Program Competitiveness, Entrepreneurship and Innovation (EPANEK) 2014-2020, Amount €500,000 - co-researcher for the Cancer Biobank of the University of Ioannina
2. Participation in the Funded Program of the Region of Epirus (New Knowledge III) entitled "Bioinformatics analysis of a large volume of genomic data of brain tumor patients and development of advanced algorithms for finding biomarkers and predicting the possibility of cell mutations" Scientifically Responsible Professor Mr. I. Gerothanasis, Management of ELKE Ioannina, Project code 82463

## Publications

141 publications in peer-reviewed journals **Full list of Publications at:** <https://sites.google.com/uoi.gr/eleftheria-hatzimichael>

### 10 most cited Publications

Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs. Londina, E., Lohera, P., Telonis, A.G., ...Fortina, P., Rigoutsos, I. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(10), pp. E1106–E1115, **327 Citations**

MEG3 imprinted gene contribution in tumorigenesis, Benetatos, L., Vartholomatos, G., Hatzimichael, E. International Journal of Cancer, 2011, 129(4), pp. 773–779, **256 Citations**

The microRNAs within the DLK1-DIO3 genomic region: Involvement in disease pathogenesis, Benetatos, L., Hatzimichael, E., Londin, E., ...Rigoutsos, I., Briasoulis, E. Cellular and Molecular Life Sciences, 2013, 70(5), pp. 795–814, **224 Citations**

The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Powles, T., Stebbing, J., Bazeos, A., ...Gazzard, B., Bower, M. Annals of Oncology, 2009, 20(4), pp. 775–779, **140 Citations**

CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Benetatos, L., Hatzimichael, E., Dasoula, A., ...Georgiou, I., Bourantas, K.L. Leukemia Research, 2010, 34(2), pp. 148–153, **139 Citations**

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Syed, N., Langer, J., Janczar, K., ...Roncaroli, F., Crook, T. Cell Death and Disease, 2013, 4(1), **139 Citations**

Hematopoietic stem cell transplantation. Hatzimichael, E., Tuthill, M. Stem Cells and Cloning: Advances and Applications, 2010, 3(1), pp. 105–117, **122 Citations**

Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Panteli, K.E., Hatzimichael, E.C., Bouranta, P.K., ...Stebbing, J., Bourantas, K.L. British Journal of Haematology, 2005, 130(5), pp. 709–715, 106 **112 Citation**

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Delage, B., Luong, P., Maharaj, L., ...Chen, L.-T., Szlosarek, P.W. Cell Death and Disease, 2012, 3(7), e342, **106 Citations**

The role of cytokines in sickle cell disease. Makis, A.C., Hatzimichael, E.C., Bourantas, K.L. Annals of Hematology, 2000, 79(8), pp. 407–413, **95 Citations**

### Citations - As of October 2024

Source Scopus 3770 (excluding self-citations of all authors 3705), **h-index (source Scopus) 33**

Source Google Scholar 5752, **h-index (source Google Scholar) 40, i10-index 81**

## Clinical Trials

### As Primary Investigator

#### Phase IV (selected)

1. Real-world evidence of the use of a carfilzomib triplet including an anti-CD38 antibody in patients with multiple myeloma who have received at least one prior therapy, Sponsor Amgen
2. Models of Treatment in Real Conditions and Clinical Outcomes in Unsuitable Patients with AML in Greece Who Receive First Line Systematic Treatment or the Best Supportive Care, the SECURE study
3. Prospective non-invasive study to describe its efficacy and safety as first-line treatment in patients with acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy in routine clinical practice in Greece, the SURVIVE study
4. MiraCLLe Study: An Epidemiological, Prospective, two-year cohort study to Record the True First- and Second-Line Treatment Strategy, in Daily Clinical Practice, Treatment Results in Left-Sided Greece, Quality of Life in Longevity, Sponsor Astra Zeneca
5. P19-568/Concrete: Clinical outcomes of relapse/refractory Chronic Lymphocytic Leukemia (R/R CLL) patients treated with venetoclax in routine clinical settings in Greece, Sponsor: AbbVie
6. Retrospective analysis of clinical outcomes of patients with relapsing / refractory Chronic Lymphocytic Leukemia (R/R CLL) treated with venetoclax: Retrospective analysis from Greece, Sponsor: AbbVie

#### Phase II-III (selected)

1. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
2. Phase 3 Randomized, Controlled Study of Blinatumomab Alternating with Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
3. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
4. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
5. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
6. A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1), Sponsor Abbvie
7. A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
8. A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients (CPI 0610-04, MANIFEST-2)
9. A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

10. A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PvD) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8), Sponsor GlaxoSmithKline
11. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of MM with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor Amgen
12. A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of IMP in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP), Sponsor: UCB Biopharma SRL
13. Study M20-638: A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to Rituximab and Lenalidomide (R2) alone in Subjects with Relapsed or Refractory Follicular Lymphoma, Sponsor: AbbVie
14. Study M20-621: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma Version Number: 1.0, Sponsor: AbbVie
15. PCYC-1143-CA: A Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma, Sponsor: Pharmacyclics
16. ASPER-III-19-1: A phase 3, double-blind, multicentric, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Itraconazole dry powder for inhalation for the prevention of invasive mould disease in patients with Acute Leukaemia and Neutropaenia, Sponsor: Laboratoires SMB S.A
17. A phase III, randomized, open-label, active-controlled, multicenter study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with paroxysmal nocturnal hemoglobinuria not previously treated with complement inhibitors, Sponsor Hoffmann-La Roche
18. An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd), Sponsor: Amgen
19. A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2), Sponsor: Novartis

#### As Subinvestigator in 25 Phase II-IV

---

#### Organizational - administrative experience

- Secretary of the Steering Committee of the Scientific Department of Myelodysplastic Syndromes and Marrow Failure of the Hellenic Society of Hematology, 2022-2023, 2024-2025
  - Member of the Board of Directors of the Hellenic Society of Hematology, 2022-2024
  - President of the Interscience Society for Research in Hematology, 2021
  - President of the Scientific Committee of the 15th International Forum of Medical Students and Young Doctors, April 16-18, 2021
  - Organization of the external Hematology Clinic, G.N. "C. Hatzikosta", June 2017
  - Member of the Scientific Society of Hellenic Medical Students Publications Committee and Editor-in-Chief of the Journal In Vivo medicine for the Ioannina Branch in the academic year 1997-1998 and 1998-1999
19. Collaboration from diagnosis to post-treatment. December 17, 2011, Ioannina

### Member of Scientific Societies

- **Member of the Board of directors** Hellenic Society of Haematology
- **Secretary** of the Steering Committee of the Hellenic Myelodysplastic and Bone Marrow Failure Syndromes, Hellenic Society of Haematology
- Member American Society of Haematology, European Haematology, Association, European Association for Cancer Research
- Member of EORTC, Member of ELN

### Member of Editorial Boards

- Frontiers in Medicine (section Hematology), Diseases (Section Oncology), American Journal of Blood Research